Navigation Links
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
Date:8/7/2008

NEW YORK, Aug. 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Monday, August 11, 2008 at 8:30 a.m. EDT to discuss the second quarter 2008 financial results. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the conference call, please call 1-877-719-9788 (U.S.), 1-719-325-4769 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

The press release announcing our financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Contact: Lauren Fischer, +1-212-531-5965


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
4. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
5. Keryx Biopharmaceuticals Receives Nasdaq Notification
6. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
7. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
8. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
9. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
11. Keryx Biopharmaceuticals Announces Additions to Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... September 16, 2019 , ... When a lot of researchers think of Visikol, ... complete 3D characterization of tissues through the use of confocal and light sheet microscopy. ... and advanced cell culture focused contract research organization and today offers 3D tissue ...
(Date:9/11/2019)... ... September 09, 2019 , ... Tunnell ... government agencies, announced that its president and CEO Maryann Gallivan has been accepted ... , The Forbes Council accepted Gallivan based on the role she and ...
(Date:9/11/2019)... , ... September 10, 2019 , ... ... manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced ... be held at the Bausparkasse Schwäbisch Hall AG, Schwabisch Hall, Germany, on Sept. ...
(Date:9/8/2019)... ... September 05, 2019 , ... Spartan Bioscience, the leader ... Finance for Shopify, has been named Chief Financial Officer. , Spartan has ... as strategic advisors. Additionally, Spartan has hired Steve Edgett as Executive Vice President ...
Breaking Biology Technology:
(Date:9/22/2019)... ... September 20, 2019 , ... A new ... client demands for precision medicine products. The report, Lab Instrumentation Markets for ... 2018, the pharma/bio sector is the largest source of demand for laboratory instrumentation. ...
(Date:9/17/2019)... ... 17, 2019 , ... Dual-board certified periodontist and implant surgeon, ... of Implant Dentistry (ASID) Accreditation Courses. His lecture, “Understanding the Soft and Hard ... Modern Implant Dentistry course. Dr. Kim’s expertise comes from years of experience providing ...
(Date:9/11/2019)... ... ... Greenberg Traurig, LLP attorneys Stephen Baird , - Marcella C. ... 9-10, at the Hyatt Regency, Minneapolis. Greenberg Traurig is a founding sponsor of DeviceTalks, ... have been featured speakers at every DeviceTalks conference since 2011. , On Sept. 9, ...
Breaking Biology News(10 mins):